Biomedical Occupation or Discipline – Page 27

BioNTech Secures $145M from CEPI to Expand mRNA Vaccine Production in Africa

12 months ago talkbio0Tagged Africa, BioNTech, CEPI, equity, mRNA Vaccine, public health medicine (field), Vaccines

BioNTech, CEPI, mRNA vaccine production, Africa, vaccine equity, public health security

Merck & Co. Revives Ophthalmology Efforts with $3 Billion EyeBio Acquisition ###

12 months ago talkbio0Tagged Acquisition (action), Biotechnology, EyeBio, Merck & Co., Ophthalmology specialty, Trispecific Antibody

Merck & Co., EyeBio, Ophthalmology, Trispecific antibody, Restoret, Acquisition, Biotechnology, Pharmaceuticals

ExpressionEdits Secures $13M in Seed Funding to Revolutionize Protein Therapies with AI-Driven Intronization Technology

12 months ago talkbio0Tagged Biotechnology, ExpressionEdits, intronization, Plant seeds, protein expression, protein therapies, Technology

ExpressionEdits, Protein therapies, AI-driven intronization technology, Seed funding, Biotechnology, Protein expression

Repare Backer Amplitude Ventures Launches $192M Biotech Fund for Development and Growth

12 months ago talkbio0Tagged Amplitude, biotech fund, Biotechnology, development aspects, Growth, Investments, Repare, Ventures

Amplitude Ventures, biotech fund, Repare Therapeutics, development, growth, investment, biotechnology

Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial

12 months ago talkbio0Tagged Johnson and Johnson, Major Depressive Disorder, Mental Depression, Neuroscience discipline, Phase 3 trial, Seltorexant, Sleeplessness, Symptoms aspect

Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment

BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion

12 months ago talkbio0Tagged ADC, alliance, BioNTech, gene therapy, MediLink, Molecular Biology, oligonucleotide therapy, therapeutic autologous dendritic cells

BioNTech, MediLink, ADC alliance, $1.8 billion, oligonucleotide therapy, gene therapy, molecular biology

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

12 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks

12 months ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Cessation of life, Clinical Trials, dosing, Drug Development, Flexible, J&J, Johnson & Johnson, Malignant neoplasm of prostate

J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.

Exscientia Streamlines Operations, Prioritizes AI-Driven Drug Discovery

12 months ago talkbio0Tagged AI-generated pipeline, Biotechnology, Drug Discovery, Drug Industry, Efficiency, Exscientia, operational, Staff

Exscientia, AI-generated pipeline, drug discovery, staff reduction, operational efficiency, biotechnology, pharmaceutical industry

Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns

12 months ago talkbio0Tagged ARNT gene, aspects of adverse effects, Cancer Research, Clinical Trials, Drug Development, Liver, solid tumor treatment, Toxicity aspects

Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.